Optimal management of a patient with recurrent nasopharyngeal carcinoma
CNR Ibb | back to homepage
▲NavBar
Ricerca avanzata▼
Contiene: [X]      Estesa     Autori: [X]  Tipo di lavoro: [X]   Data iniziale: Data finale: [X]      Sede: Affiliazione IBB     
    
[Pulisci modulo]


Optimal management of a patient with recurrent nasopharyngeal carcinoma (94 visite)

Perri F, Dell'Oca I, Muto P, Schiavone C, Aversa C, Fulciniti F, Solla R, Scarpati GD, Buonerba C, Di Lorenzo G, Caponigro F

World Journal Of Clinical Cases (ISSN: 2307-8960), 2014; 2(7): 297-300.



Tipo di articolo: Journal Article,

Impact factor: 0.895, Impact factor a 5 anni: 1.273

Url: Non disponibile.

Parole chiave: Cetuximab, Nasopharyngeal Carcinoma, Re-Irradiation, Surgery Of Metastases, Undifferentiated,

Affiliazioni:

*** IBB - CNR ***
Francesco Perri, Francesco Caponigro, Head and Neck Medical Oncology Unit, National Tumor Institute of Naples, 80131 Naples, Italy.


Riferimenti:

Non disponibile.

Nasopharyngeal carcinoma is rare in western countries, accounting for less than 1% of all malignancies. Despite prognosis is satisfactory for newly diagnosed, non-metastatic disease, management of recurrent disease is challenging, with a survival expectancy of approximately 6 mo with the use of chemotherapy as the sole salvage treatment. We report a case of recurrent nasopharyngeal carcinoma treated with a combination of chemotherapy, radiotherapy and surgery in the context of a multidisciplinary approach. A durable complete response was achieved.
Nessun risultato.
Nessun risultato.

Ricerca avanzata▼
Contiene: [X]      Estesa     Autori: [X]  Tipo di lavoro: [X]   Data iniziale: Data finale: [X]      Sede: Affiliazione IBB     
    
[Pulisci modulo]
Vai a fine pagina   Versione per copia e incolla facile   Esporta tutto in BibTeX   Esporta tutto in EndNote


Perri F, Della Vittoria Scarpati G, Caponigro F, Ionna F, Longo F, Buonopane S, Muto P, Di Marzo M, Pisconti S, Solla R
* Management of recurrent nasopharyngeal carcinoma: current perspectives (3 visite)
Onco Targets Ther (ISSN: 1178-6930linking), 2019 Feb 26; 12: 1583-1591.
Impact Factor:
Dettagli    Esporta in BibTeX    Esporta in EndNote

Perri F, Pacelli R, Della Vittoria Scarpati G, Cella L, Giuliano M, Caponigro F, Pepe S
* Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications (159 visite)
HEAD NECK-J SCI SPEC (ISSN: 1043-3074), 2015; 37(5): 763-770.
Impact Factor: 2.76
Dettagli    Esporta in BibTeX    Esporta in EndNote

Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani BM, Parsons SJ, De Placido S, Bianco R
* Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models (147 visite)
Breast Cancer Res Biomed Central Ltd (ISSN: 1465-5411), 2014; 16(3): R45-R45.
Impact Factor: 0.635
Dettagli    Esporta in BibTeX    Esporta in EndNote

Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marf G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R
* Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models (149 visite)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2013 Jan 1; 19(1): 138-147.
Impact Factor: 8.193
Dettagli    Esporta in BibTeX    Esporta in EndNote

Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F
* Complete Response To Preoperative Chemoradiation And Survival In Esophageal Cancer: A Pooled Analysis Of Three Single-Institution Phase Ii Trials (160 visite)
Diseases Of The Esophagus, 2012 Feb; 142(5): 130-136.
Impact Factor: 2.057
Dettagli    Esporta in BibTeX    Esporta in EndNote

Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (168 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
Dettagli    Esporta in BibTeX    Esporta in EndNote

Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A, Salvatore M
* PET/CT in cancer research: From preclinical to clinical applications (242 visite)
Contrast Media Mol Imaging (ISSN: 1555-4309, 1555-4309linking), 2010 Jul; 5(4): 190-200.
Impact Factor: 4.02
Dettagli    Esporta in BibTeX    Esporta in EndNote

Alberobello AT, D'Esposito V, Marasco D, Doti N, Ruvo M, Bianco R, Tortora G, Esposito I, Fiory F, Miele C, Beguinot F, Formisano P
* Selective Disruption of Insulin-like Growth Factor-1 (IGF-1) Signaling via Phosphoinositide-dependent Kinase-1 Prevents the Protective Effect of IGF-1 on Human Cancer Cell Death (112 visite)
J Biol Chem Journal Of Biological Chemistry (ISSN: 0021-9258, 1083-351x), 2010 Feb 26; 285(9): 6563-6572.
Impact Factor: 5.328
Dettagli    Esporta in BibTeX    Esporta in EndNote

Storto G, Nicolai E, Salvatore M
* [18F]FDG-PET-CT for early monitoring of tumor response: When and why (148 visite)
Q J Nucl Med Mol Imaging (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2009 Apr; 53(2): 167-180.
Impact Factor: 1.724
Dettagli    Esporta in BibTeX    Esporta in EndNote

Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M
* Nuclear imaging in cancer theranostics (235 visite)
Q J Nucl Med Mol Imaging (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2007 Jun; 51(2): 152-163.
Impact Factor: 1.724
Dettagli    Esporta in BibTeX    Esporta in EndNote

Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M, Montella L
* Cetuximab is an active treatment of metastatic and chemorefractory thymoma (101 visite)
Frontiers In Bioscience (ISSN: 1093-9946, 1093-4715), 2007 Jan 1; 12(2): 757-761.
Impact Factor: 2.989
Dettagli    Esporta in BibTeX    Esporta in EndNote



11 Records (10 escludendo Abstract e Conferenze).
Impact factor totale: 34.466 (33.831 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 34.682 (34.107 escludendo Abstract e Conferenze).







    Esporta in BibTeX    Esporta in EndNote